Search

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

12.49 -1.03

Overview

Share price change

24h

Current

Min

11.76

Max

12.54

Key metrics

By Trading Economics

Income

-8.9M

-8M

Sales

3.7M

139M

P/E

Sector Avg

125.6

57.371

Profit margin

-5.724

Employees

1,790

EBITDA

18M

4M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+14.95% upside

Market Stats

By TradingEconomics

Market Cap

271M

2.2B

Previous open

13.52

Previous close

12.49

News Sentiment

By Acuity

100%

0%

326 / 340 Ranking in Healthcare

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 sie 2026, 23:56 UTC

News

Wayfair shares rise in after-market hours after Rosenblatt analyst Scott Devitt initiated coverage with a Buy rating and a price target of $125.00.

19 sie 2026, 23:56 UTC

News
Social Media

Cogent Communications is facing a class action lawsuit over alleged false statements, contributing to a decline in shares during after-market hours.

19 sie 2026, 23:52 UTC

News
Correlated Moves

Cohen & Steers Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines. The fund declared a monthly dividend of $0.126 per share.

19 sie 2026, 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

19 sie 2026, 23:51 UTC

News
Social Media

Ultragenyx Pharmaceutical received FDA accelerated approval for its gene therapy GENGLYCOS, leading shares to rise sharply in after-market hours.

19 sie 2026, 23:41 UTC

News

Target Corp shares are lower in after-market hours despite stronger-than-expected second-quarter earnings of $4.11 per share and a raised full-year forecast.

19 sie 2026, 23:36 UTC

News
Social Media

Rosenblatt analyst Scott Devitt initiated coverage on Amazon.com with a Buy rating. Shares advanced in after-market trading following this positive assessment.

19 sie 2026, 23:31 UTC

News

Wendy's Co shares are lower in after-market hours following a management reset and reports of Trian Fund Management exploring a potential buyout.

19 sie 2026, 23:26 UTC

News

Constellation Brands announced a $100 million investment over five years to support farmers in Idaho, Montana, and North Dakota. Shares were roughly flat in after-market trading.

19 sie 2026, 23:22 UTC

News
Social Media
Correlated Moves

Coinbase Global Inc shares are higher in after-market trading amid bullish social media sentiment and the announcement of direct USDC trading in Brazil.

19 sie 2026, 23:21 UTC

Social Media
Correlated Moves
News

Marvell Technology shares rise in after-hours trading following a significant deal with Google, which includes a warrant for 58.97 million shares at $206.58 each.

19 sie 2026, 23:21 UTC

Correlated Moves
News

Microstrategy Inc. shares rose in after-market trading, driven by increased bullish options activity and positive remarks on its Bitcoin strategy from executives.

19 sie 2026, 23:21 UTC

News

Kratos Defense shares are rising in after-market trading as the U.S. Air Force evaluates alternatives to existing aerial targets, including the BQM-167A.

19 sie 2026, 23:21 UTC

Event
Social Media
News

BILL Holdings reported strong Q4 results, with adjusted net income of $94 million. Shares are higher in after-hours trading following the earnings report.

19 sie 2026, 23:16 UTC

News

Accuray Inc shares fell in after-market hours following a net loss of $1.94 million and revenue of $100.92 million, missing expectations.

19 sie 2026, 23:16 UTC

News
Social Media

Iovance Biotherapeutics shares reached a new 52-week high amid positive melanoma treatment sector sentiment and an anticipated revenue guidance increase.

19 sie 2026, 23:16 UTC

News
Social Media

Netflix Inc. is trading higher in after-market hours amid reports of competitive strategies in the streaming industry, including YouTube's incentives for exclusive content.

19 sie 2026, 23:11 UTC

News

Carlyle Group invests in Castelion's $1 billion funding round, boosting defense sector engagement. Shares are higher in after-market trading following the announcement.

19 sie 2026, 23:11 UTC

News

Northrop Grumman declared a quarterly dividend of $2.47 per share, contributing to shares trading higher in after-market hours.

19 sie 2026, 23:11 UTC

Correlated Moves
News

The Australian Dollar is gaining against the Hong Kong Dollar amid rising global bond yields and inflation concerns linked to geopolitical tensions.

19 sie 2026, 23:06 UTC

News

Replimune Group shares declined in after-market hours following the grant of equity awards to Chief Commercial Officer Michelle DiNapoli, raising potential dilution concerns.

19 sie 2026, 23:06 UTC

News

Ionis Pharmaceuticals is advancing RG-6299 into a pivotal Phase III trial for IgA nephropathy in collaboration with Roche and Chugai. Shares are higher in after-market trading.

19 sie 2026, 23:06 UTC

Social Media
News

Hims & Hers Health Inc. shares are lower in after-market trading following a lawsuit from the FTC alleging deceptive practices regarding user privacy and billing.

19 sie 2026, 23:06 UTC

News

Chewy Inc shares are lower in after-market trading as cautious sentiment grows ahead of the September earnings call and a Neutral rating from Rosenblatt.

19 sie 2026, 23:06 UTC

News
Correlated Moves

Geopolitical tensions and Fed concerns contribute to a decline in the iShares 20+ Year Treasury Bond ETF in after-market trading. The iShares TIPS Bond ETF also moves lower.

19 sie 2026, 23:06 UTC

Social Media
News

SPDR Gold Shares trade higher after-market, boosted by social media discussions on its return above the 200-day moving average amid geopolitical tensions and inflation concerns.

19 sie 2026, 23:06 UTC

News
Correlated Moves

Geopolitical tensions and inflation concerns support iShares Silver Trust's gains during after-market hours, maintaining a position above its 20-day moving average.

19 sie 2026, 23:06 UTC

Correlated Moves
News

Northern Oil and Gas announced a $500 million senior notes offering, contributing to a decline in shares during after-market trading. EOG also fell amid sector dynamics.

19 sie 2026, 23:06 UTC

News
Correlated Moves

Twist Bioscience Corp shares are lower in after-market hours following a critical short report from Scorpion Capital questioning the company's AI-driven protein design strategy.

19 sie 2026, 23:02 UTC

News

Encore Capital Group appoints Robert Beck to its board, effective immediately. The move has contributed to shares rising in after-market trading.

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

14.95% upside

12 Months Forecast

Average 14.53 USD  14.95%

High 16 USD

Low 13.6 USD

Based on 3 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat